Beleave Inc. (CNSX:BE) (“Beleave” or the “Company“) is pleased to announce that it has entered into an interim streaming agreement with PanCann Streaming Corp. (“PanCann“) to finance the purchase and construction of a proposed second production facility to be identified, in exchange for equity participation in, and a production yield allocation from the proposed facility.
This agreement, if funded, would allow Beleave to substantially increase its potential production capacity on a non-dilutive basis to Beleave’s shareholders.
Key Terms of the Agreement:
The parties will work cooperatively to identify an appropriate second site to be acquired and developed by a newly formed special purpose subsidiary of Beleave (“NewCo“).
The proposed second site is expected to be located in Ontario and will be designed to accommodate 200,000 square feet of cultivation space.
Once such a site and the construction budget for the new facility have been agreed on, PanCann will provide, among other things, (i) up to $5 million to fund the purchase of the second site and (ii) all necessary funding to complete the construction of the new facility. In return, PanCann will receive a 50% equity interest in NewCo and 50% of the proceeds (net of certain costs) of future wholesale or retail sales completed by NewCo.
“This opportunity allows Beleave to add supply beyond its current expansion plans, as well as explore wholesale opportunities that will not interfere with our potential patient sales in the future. This will increase our top line while eliminating the need for capital expenditure,” says Roger Ferreira, CEO and Director of Beleave. “A completely accretive agreement for Beleave Inc., and the start of a new and exciting partnership with PanCann.”
The agreement remains subject to a number of precedent conditions, including availability of financing on the part of PanCann, receipt by Beleave of applicable Health Canada and other regulatory approvals, due diligence by the parties, execution of definitive agreements, and the ability of the parties to agree on future construction budgets and timelines. There is no assurance that the PanCann financing will be completed on the terms contemplated herein or at all.
About Beleave
Beleave Inc. is a biotech company committed to becoming a licensed producer under the Access to Cannabis for Medical Purposes Regulations (the “ACMPR”). Beleave’s wholly-owned subsidiary First Access Medical Inc. (“FAM”) has applied for a license to cultivate and sell medical cannabis pursuant to the ACMPR. As of the date hereof, FAM has successfully advanced past the review stage, and completed its pre-licensing inspection. Beleave’s purpose-built facility is located near Hamilton, Ontario.
Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Company’s current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. In particular, this release contains forward-looking information relating to the proposed transaction with PanCann. The proposed transaction is subject to a number of material conditions. It is also subject to a number of termination rights exercisable by either party. There is no assurance that funding from PanCann will be completed on the terms contemplated herein or at all, nor as to the timing of any such funding. In the absence of funding from PanCann, Beleave may be unable to fund its intended expansion on a non-dilutive basis or at all. Even if funding from Pancann is completed, Beleave would remain responsible for certain material operating costs relating to its proposed second site expansion. Please refer to the Company’s SEDAR filings for further risks, including Health Canada and other regulatory licensing risks, that are relevant to Beleave’s business generally and should be considered in connection with its proposed transaction with PanCann. The forward-looking information contained in this press release is made as of the date hereof and the Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward-looking information. The foregoing statements expressly qualify any forward-looking information contained herein.

Source: www.marketwired.com

Khiron Life Sciences Corp. (“ Khiron ” or, the “ Company ”) (TSXV: KHRN), (OTCQB: KHRNF), (Frankfurt: A2JMZC), announced today that it has re-filed its unaudited condensed interim consolidated financial statements, together with the notes thereto, for the three and six months ended June 30, 2020 and 2019 (the “ Interim Financial Statements ”) to correct, among other things, certain 2019 comparative period information and to update certain presentation arising from the Company’s early adoption of IFRS 3 in late 2019, which changes were identified in connection with the Company’s review engagement with its auditor. The Company does not consider these adjustments either individually nor in the aggregate, to be material.

The re-filed Interim Financial Statements reflect changes to the Condensed Interim Consolidated Statements of Loss and Comprehensive Loss comparative period to remove transaction fees from the income statement and capitalize them to the applicable acquisition in accordance with the Company’s early adoption of the amended IFRS 3 as set out in Note 2, and to reclassify $1 million from general and administrative expenses to transaction fees for presentation purposes to conform with the Company’s presentation used in its audited consolidated financial statements for the years ended December 31, 2019 and 2018 (the “ Audited Annual Financial Statements ”). The re-filed interim Financial Statements also reflect changes to the Condensed Interim Consolidated Statement of Changes in Shareholders’ Equity to correct the 2019 comparative period balances as they incorrectly reflect Q1 2019 period balances, update certain presentation to conform with the Company’s presentation used in its Audited Annual Financial Statements; and reduce the valuation conclusion of the Company’s acquisition of NettaGrowth International Inc. to conform with the Audited Annual Financial Statements. The re-filed Interim Financial Statements also bring forward the subsequent event note disclosure.

Keep reading... Show less

Part of “Rooted in Good” CSR Platform, “Feed the Block” Gives Back Through Strategic Social Partnerships with Local Organizations Focused on Food Insecurity

Curaleaf Holdings, Inc. (CSE: CURA) (OTCQX: CURLF) (“Curaleaf” or the “Company”), a leading U.S. provider of consumer products in cannabis, today announced a multi-state fundraising initiative in which proceeds will benefit 24 locally run food banks, homeless shelters and nonprofits working to proactively address the needs of those facing food insecurity in communities across America. This effort is a part of the Strategic Social Partnerships pillar within Curaleaf’s “Rooted in Good” Corporate Social Responsibility platform.

Keep reading... Show less

On September 8, 2020, Aurora Cannabis Inc. (NYSE:ACB) stunned the market when it announced that it expected to record up to $1.8 billion in goodwill impairment charges in the fourth quarter of 2020. On the same day, Aurora also announced a charge of approximately $140 million in the carrying value of certain inventory, and that it was appointing a new chief executive officer. On this news, Aurora’s stock fell approximately 11.6% in just one day. Since May 2020, Aurora’s stock is down approximately $10.00 per share

A lawsuit alleging violations of federal securities laws has been filed against Aurora and certain of its officers and directors. The suit alleges, among other things, that Aurora misled investors as to the value of prior acquisitions, that the Company had experienced degradation in certain assets, and that as a result, it was foreseeable that Aurora would record significant goodwill and asset impairment charges. According to the lawsuit, this news was so shocking because Aurora had previously lauded a “business transformation plan” that would purportedly “better align the business financially with the current realities of the cannabis market.”

Keep reading... Show less

  • Exclusive patent licensed from University of Idaho.
  • Mustard-derived fumigation of stored food – targeting vegetables and potatoes.
  • Leading agrochemical for sprout suppression – chlorpropham – banned by European Union on Oct. 8, 2020.
  • Appointment of Scientific Advisor Dr. Matthew J. Morra, professor emeritus of soil biochemistry at University of Idaho.

 MustGrow Biologics Corp. (CSE: MGRO) (OTCQB: MGROF) (FSE: 0C0) (the “Company”, “MustGrow”) is pleased to announce the exclusive patent licensing from the University of Idaho pertaining to a natural biopesticide mustard-based treatment of stored produce and other foods, particularly sprout suppression of potatoes.

Keep reading... Show less

Study represents the first research completed on the long-term toxicity and lifespan effects of cannabidiol in the preclinical model C. elegans

Canopy Growth Corporation (“Canopy Growth” or the “Company”) (TSX: WEED) (NASDAQ: CGC) and its medical division, Spectrum Therapeutics, have completed and published a new study on the long-term effects of cannabidiol (CBD), specifically focusing on toxicity and lifespan effects of CBD in the preclinical model C. elegans.

Keep reading... Show less